Security Notice: Please be aware of impersonation attempts using our company name
Legitimate communications from Ascent Research will only come from official @ascentresearch.com email addresses.
Quick Order Cart

Cat. No. ARG33591

GPSM1 Knockout A549 Polyclonal Cells

  • Product Type:

    Polyclonal Cell Population

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Lung

  • Disease:

    Lung adenocarcinoma

The GPSM1 knockout A-549 polyclonal cells provide a CRISPR/Cas9-edited polyclonal population of human lung adenocarcinoma cells with targeted disruption of the GPSM1 gene. GPSM1 acts as a GDI for G??i subunits and plays a central role in mitotic spindle orientation, autophagy regulation, and cell migration through interactions with GPSM2, NUMA1, and G-protein signaling components. This model, derived from KRAS and p53 wild-type A-549 cells, is ideal for studying asymmetric cell division, GPCR-independent signaling, autophagy flux, and cancer cell invasion. Applications include high-content spindle imaging, migration assays, and biochemical analysis of the GPSM1-G??i-GPSM2 complex. For further details, contact Ascent Research.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    A549

    Sex of Donor

    Male

    Age

    58 years

    Derived From Site

    Lung

    Gene Name

    GPSM1

    Gene Identifier

    NCBI Gene ID 26086

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Growth medium

    MEM

    Supplement(s)

    10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

GPSM1 knockout A-549 polyclonal cells are a CRISPR/Cas9-edited polyclonal cell population derived from the A-549 lung adenocarcinoma line, targeting the GPSM1 gene. This product comprises a heterogeneous pool of non-clonal cells harboring diverse loss-of-function mutations across the GPSM1 coding region, enabling robust analysis of GPSM1-dependent functions. As a polyclonal knockout model, it retains population-level heterogeneity, making it particularly suitable for cancer biology and signaling studies without the biases introduced by single-cell cloning.

The parental A-549 cell line is an adherent human alveolar basal epithelial model of non-small cell lung carcinoma (NSCLC) with wild-type KRAS and p53 alleles. Unlike many NSCLC lines that carry oncogenic KRAS or p53 mutations, A-549 provides a genetically unperturbed background for studying tumor-suppressive and oncogenic pathways. Its epithelial morphology and well-characterized signaling landscape make it a standard host for cancer cell biology, drug response, and signal transduction research.

GPSM1 functions as a guanine nucleotide dissociation inhibitor (GDI) that stabilizes the inactive GDP-bound state of G??i subunits (GNAI1/2/3), suppressing GPCR-dependent and -independent G-protein signaling. In mitotic spindle orientation, GPSM1 assembles a cortical complex with G??i-GDP, GPSM2/LGN, NUMA1, and Inscuteable (INSC), linking spindle poles to polarity cues. GPSM1 also promotes autophagy by inhibiting mTORC1, acting upstream of the ULK1 complex, and regulates cell migration and invasion through G?¦? effectors. Upstream, GPSM1 expression is activated by Wnt/??-catenin signaling and regulated by mTORC1 and ubiquitin-mediated degradation. Downstream, it modulates cAMP levels via adenylate cyclase, interacts with PI3K/AKT signaling, and influences planar cell polarity and Notch pathway crosstalk.

In A-549 lung adenocarcinoma cells, GPSM1 knockout enables dissection of its roles in asymmetric division, autophagy-dependent survival, and metastasis without confounding KRAS or p53 mutations. The wild-type p53 backdrop permits analysis of autophagy regulation under genotoxic stress, while the absence of constitutive RAS signaling allows clear investigation of GPSM1-driven migration and invasion. This model is ideal for exploring how spindle orientation defects contribute to aneuploidy and tumor heterogeneity, and for studying GPSM1’s integration with planar cell polarity and Notch pathways in epithelial cancers.

Key applications include high-content imaging of spindle/NuMA, transwell migration/invasion assays, and autophagy flux measurements by LC3 turnover. Biochemical validation employs co-immunoprecipitation of the GPSM1-G??i-GPSM2 complex, cAMP assays, and phospho-AKT immunoblotting. The polyclonal population is also suited for GPCR-independent signaling studies and small-molecule screens targeting spindle orientation defects. For technical or purchasing inquiries, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)